dapagliflozine hcs 5 mg compr. pellic.
hcs s.p.r.l.-b.v.b.a. - dapagliflozine propanediol monohydraté 6,15 mg - eq. dapagliflozine 5 mg - comprimé pelliculé - dapagliflozin
dapagliflozine hcs 10 mg compr. pellic.
hcs s.p.r.l.-b.v.b.a. - dapagliflozine propanediol monohydraté 12,3 mg - eq. dapagliflozine 10 mg - comprimé pelliculé - dapagliflozin
xigduo comprimé
astrazeneca canada inc - dapagliflozine (propanediol de dapagliflozine monohydraté); chlorhydrate de metformine - comprimé - 5mg; 850mg - dapagliflozine (propanediol de dapagliflozine monohydraté) 5mg; chlorhydrate de metformine 850mg - biguanides
xigduo comprimé
astrazeneca canada inc - dapagliflozine (propanediol de dapagliflozine monohydraté); chlorhydrate de metformine - comprimé - 5mg; 1000mg - dapagliflozine (propanediol de dapagliflozine monohydraté) 5mg; chlorhydrate de metformine 1000mg - biguanides
forxiga comprimé
astrazeneca canada inc - dapagliflozine (propanediol de dapagliflozine monohydraté) - comprimé - 5mg - dapagliflozine (propanediol de dapagliflozine monohydraté) 5mg - sodium-glucose cotransporter 2 (sglt2) inhibitors
forxiga comprimé
astrazeneca canada inc - dapagliflozine (propanediol de dapagliflozine monohydraté) - comprimé - 10mg - dapagliflozine (propanediol de dapagliflozine monohydraté) 10mg - sodium-glucose cotransporter 2 (sglt2) inhibitors
edistride
astrazeneca ab - dapagliflozine propanediol monohydraté - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - les médicaments utilisés dans le diabète - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. en outre, à d'autres médicaments pour le traitement du diabète de type 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 et 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.
forxiga
astrazeneca ab - dapagliflozine propanediol monohydraté - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - les médicaments utilisés dans le diabète - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. en outre, à d'autres médicaments pour le traitement du diabète de type 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 et 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.
qtern comprimé
astrazeneca canada inc - saxagliptine (chlorhydrate de saxagliptine); dapagliflozine (propanediol de dapagliflozine monohydraté) - comprimé - 5mg; 5mg - saxagliptine (chlorhydrate de saxagliptine) 5mg; dapagliflozine (propanediol de dapagliflozine monohydraté) 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors
qtern comprimé
astrazeneca canada inc - saxagliptine (chlorhydrate de saxagliptine); dapagliflozine (propanediol de dapagliflozine monohydraté) - comprimé - 5mg; 10mg - saxagliptine (chlorhydrate de saxagliptine) 5mg; dapagliflozine (propanediol de dapagliflozine monohydraté) 10mg - dipeptidyl peptidase-4 (dpp-4) inhibitors